Activin and Inhibin

EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC 50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activityForm:SolidIC50&amp: Target:EZH2 64 nM

EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC 50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activityForm:SolidIC50&amp: Target:EZH2 64 nM

EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC 50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activityForm:SolidIC50&amp: Target:EZH2 64 nM

EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC 50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activityForm:SolidIC50&amp: Target:EZH2 64 nM

EZH2-IN-2 is a EZH2 inhibitor extracted from patent WO2018133795A1, Compound Example 69, with an IC 50 of 64 nM. EZH2-IN-2 can be used for the research of cancer or precancerous condition related to EZH2 activityIC50&amp: Target:EZH2 64 nM (IC 50 ).

EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 ( IC 50 =18 nM in SETD2 biochemical assay: IC 50 =34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large

EZM0414 is a potent, selective, orally bioavailable inhibitor of SETD2 ( IC 50 =18 nM in SETD2 biochemical assay: IC 50 =34 nM in cellular assay). EZM0414 can be used for the research of relapsed or refractory multiple myeloma and diffuse large

EZM0414 TFA is a potent, selective and orally active inhibitor of SETD2 which is a human histone methyltransferase . EZM0414 TFA has anti-proliferative effectsForm:SolidIC50&amp: Target:SETD2.

EZM0414 TFA is a potent, selective and orally active inhibitor of SETD2 which is a human histone methyltransferase . EZM0414 TFA has anti-proliferative effectsForm:SolidIC50&amp: Target:SETD2.

F13714 fumarate, a selective 5-HT1A receptor biased agonist, shows antidepressant-like properties after a single administration in the mouse model of chronic mild stressIn VitroF13714 targets 5-HT1A autoreceptors. MCE has not independently confirmed

F13714 fumarate, a selective 5-HT1A receptor biased agonist, shows antidepressant-like properties after a single administration in the mouse model of chronic mild stressIn VitroF13714 targets 5-HT1A autoreceptors. MCE has not independently confirmed

F13714 fumarate, a selective 5-HT1A receptor biased agonist, shows antidepressant-like properties after a single administration in the mouse model of chronic mild stressIn VitroF13714 targets 5-HT1A autoreceptors. MCE has not independently confirmed